Peter C. Enzinger

27.3k citations
154 papers · 20.6k · 17 hit papers · h-index 60

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Colorectal Cancer Surgical Treatments
    • Pancreatic and Hepatic Oncology Research
    • Gastric Cancer Management and Outcomes

Papers in

    • Colorectal Cancer Treatments and Studies 21
    • Pancreatic and Hepatic Oncology Research 10
    • Cancer Immunotherapy and Biomarkers 10
    • Colorectal Cancer Surgical Treatments 9
    • Gastric Cancer Management and Outcomes 47

Peter C. Enzinger

148 papers receiving 20.2k citations

Peter C. Enzinger's Hit Papers

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology 2025 · 70 citations
700+2+5Years since publication4008001.2k

Peers

Peter C. Enzinger
Comparison fields: 5 of 127
  • Oncology 7.3k
  • Pulmonary and Respiratory Medicine 4.2k
  • Surgery 5.7k
  • Hepatology 754
  • Cancer Research 912
Replace George A. Poultsides with:
George A. Poultsides United States
Pascal R. Hammel France
Christopher G. Willett United States
Kei Muro Japan
Dirk Arnold Germany
Joseph M. Herman United States
Steven N. Hochwald United States
David Malka France
Cristina Rosa Ferrone United States
Kenichi Sugihara Japan
Peter C. Enzinger relative to George A. Poultsides United States George A. Poultsides's profile →
Citations per field
00.5×1.5×1.9×
George A. Poultsides · 1×
Citations per year

Countries citing papers authored by Peter C. Enzinger

Since Specialization
Citations

This map shows the geographic impact of Peter C. Enzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C. Enzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C. Enzinger more than expected).

Fields of papers citing papers by Peter C. Enzinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C. Enzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C. Enzinger. The network helps show where Peter C. Enzinger may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter C. Enzinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter C. Enzinger Line = papers co-authored together Peter C. Enzinger links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 154 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Esophageal Cancer
Hit paper breakdown →
20032250
2
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
Hit paper breakdown →
20181485
3
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Hit paper breakdown →
20221180
4
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Hit paper breakdown →
20211140
5
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Hit paper breakdown →
20171087
6
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
Hit paper breakdown →
2020877
7
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Hit paper breakdown →
2020837
8
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Hit paper breakdown →
2019817
9 2009593
10
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Hit paper breakdown →
2023531
11
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Hit paper breakdown →
2023428
12 2006425
13
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Hit paper breakdown →
2018405
14 2009392
15 2009391
16 2006330
17
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Hit paper breakdown →
2023328
18 2014324
19 2008316
20 2008258

About Peter C. Enzinger

Peter C. Enzinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Epidemiology and Cancer Research, having authored 154 papers that have together received 20.6k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (47 papers), Esophageal Cancer Research and Treatment (43 papers), Colorectal Cancer Treatments and Studies (21 papers), Pancreatic and Hepatic Oncology Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Surgical Treatments (9 papers), Neuroendocrine Tumor Research Advances (8 papers) and Fuel Cells and Related Materials (4 papers). The work is most often cited by research in Oncology (7.3k citations), Pulmonary and Respiratory Medicine (4.2k citations), Surgery (5.7k citations), Hepatology (754 citations) and Cancer Research (912 citations). Peter C. Enzinger has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Robert James Mayer, Charles S. Fuchs, Jeffrey William Clark, David P. Ryan, Jeffrey A. Meyerhardt, Matthew H. Kulke, Keith E. Stuart, Lawrence Scott Blaszkowsky, Alona Muzikansky and Andrew Xiuxuan Zhu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of the National Comprehensive Cancer Network, The Oncologist and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact